(Total Views: 613)
Posted On: 10/28/2021 7:28:31 AM
Post# of 148892
The Invalids have put substantial pressure on our stock since NP announced HIV as a Monotherapy and maybe even before; considering the dilution longs suffered while raising little money with previous leaders.
Their narrative was to pin point Nader as bad to sway votes for a new BOD. Our SP took a hit during the proxy battle while they were invalid all along.
The narrative stayed the same and one would think they were good reasons. However, I chose not to judge because I understand that current management has been trying to break themselves free from the invalids self-inflicting wounds laid upon us.
Leaving CROs and not putting all of our eggs in one CRO is a start of something awesome. Diversity and strategic partnerships.
One: SymBio has had over 55 FDA approvals, over 40 years of data management, over 200 clinical trials, has 1,200 clinical sites and worked with 85,000 patients.
Chris Recknor believes Long Haulers is attached to Epstein Barr virus, CVM, etc and many researchers have pointed out women suffer from LHs at a higher rate. With the data that CR has seen, it would make sense as to why this CRO is running LH.
They specialize in women health, are a world class organization and have offices in Europe as well.
CytoDyn released a PR basically stating that the FDA is allowing them to submit portions of the BLA in….regardless of what gaps to fill. A Rolling review, without the negative spin.
Voted FOR ALL, to give this company the chance to grow with Brazil, Philippines and all 60+ indications and CROs.
All these BTDs, with an effective and safety profile drug.
I’m also anticipating possible results on if the Monotherapy HIV clients taking our drug ever got Covid or Long Haulers or didn’t.
There’s so much more information we will get out of our CROs for more possible BTDs. I’m here for all of it.
Their narrative was to pin point Nader as bad to sway votes for a new BOD. Our SP took a hit during the proxy battle while they were invalid all along.
The narrative stayed the same and one would think they were good reasons. However, I chose not to judge because I understand that current management has been trying to break themselves free from the invalids self-inflicting wounds laid upon us.
Leaving CROs and not putting all of our eggs in one CRO is a start of something awesome. Diversity and strategic partnerships.
One: SymBio has had over 55 FDA approvals, over 40 years of data management, over 200 clinical trials, has 1,200 clinical sites and worked with 85,000 patients.
Chris Recknor believes Long Haulers is attached to Epstein Barr virus, CVM, etc and many researchers have pointed out women suffer from LHs at a higher rate. With the data that CR has seen, it would make sense as to why this CRO is running LH.
They specialize in women health, are a world class organization and have offices in Europe as well.
CytoDyn released a PR basically stating that the FDA is allowing them to submit portions of the BLA in….regardless of what gaps to fill. A Rolling review, without the negative spin.
Voted FOR ALL, to give this company the chance to grow with Brazil, Philippines and all 60+ indications and CROs.
All these BTDs, with an effective and safety profile drug.
I’m also anticipating possible results on if the Monotherapy HIV clients taking our drug ever got Covid or Long Haulers or didn’t.
There’s so much more information we will get out of our CROs for more possible BTDs. I’m here for all of it.
(22)
(0)Scroll down for more posts ▼
